Long-Term Safety and Efficacy of KL1333 in Adults with Primary Mitochondrial Disease
- Substances:Napazimone
Belgium- Participants:18–64 years · 65+ years
- Substances:Napazimone
- Sponsor:Pharming Technologies B.V.
Rare diseases
Investigational molecules
Locations
Back to Sweden1 405 clinical trials in Landskrona, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SwedenKliniska-Provningar.se(opens in a new tab)
BelgiumEvaluation of FG001 imaging agent in patients with oropharyngeal and oral squamous cell carcinoma undergoing transoral robotic surgery or neck dissection
DenmarkAn observational study of carbidopa and levodopa use with a new dispensing device and app in patients with Parkinson's disease
SwedenTesting inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia
SwedenA Study of SAB-142 to Slow the Progression of Type 1 Diabetes in Adults and Children Recently Diagnosed with the Disease
AustriaStudy of FG001 for Detecting Meningioma or Low-Grade Glioma in Patients Undergoing Neurosurgery
DenmarkStudy on the Safety and Effectiveness of Terbinafine Solution for Treating Mild to Moderate Nail Fungus in Children Aged 6-17 Years
DenmarkStudy on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients
SwedenStudy of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease
SwedenStudy on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer
SwedenStudy on Early Diffuse Cutaneous Systemic Sclerosis: Comparing Stem Cell Transplantation with Cyclophosphamide, Filgrastim, and Mycophenolate Mofetil
SwedenEfficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical research focusing on heart failure with preserved ejection fraction (HFpEF), evaluating the effectiveness of spironolactone and eplerenone treatments combined with standard care approaches.
The research aims to reduce hospitalization rates and improve cardiovascular survival outcomes through registry-based methodologies.
Groundbreaking research in non-muscle invasive bladder cancer treatment, comparing the efficacy of adjuvant therapies using gemcitabine versus mitomycin in intermediate-risk cases.
This study focuses on improving recurrence-free survival rates following transurethral tumor resection procedures.
Tell us about your condition – we search every trial in Europe and connect you with the right site.